Blood parameters score predicts long-term outcomes in stage II-III gastric cancer patients

Table 1 Clinicopathological characteristics of patients according to the blood parameters score in the developing and validation cohorts

Variable	Developing cohort (n = 567)				Validation cohort (n = 283)
	Total	Low-BPM (%)	High-BPM (%)	P value	Total	Low-BPM (%)	High-BPM (%)	P value
Age (yr, mean ± SD)		58.8 (± 11.3)	64.6 (± 10.1)	< 0.001		59.5 (± 11.5)	65.5 (± 9.5)	< 0.001
Sex				0.409				0.193
Male	430	218 (74.4)	212 (77.4)		226	113 (76.9)	113 (83.1)
Female	137	75 (25.6)	62 (22.6)		57	34 (23.1)	23 (16.9)
Body mass index (mean ± SD)		22.3 (± 2.8)	21.8 (± 3.0)	0.038		22.1 (± 2.6)	21.7 (± 3.1)	0.285
Tumor stage				< 0.001				0.004
II a	86	58 (19.8)	79 (28.8)		61	39 (26.5)	22 (16.2)
II b	93	42 (14.3)	51 (18.6)		45	25 (17.0)	20 (14.7)
III a	142	89 (30.4)	53 (19.3)		63	33 (22.4)	30 (22.1)
III b	148	71 (24.2)	77 (28.1)		66	33 (22.4)	30 (22.1)
III c	98	33 (11.3)	65 (23.7)		48	17(11.6)	31 (22.8)
Tumor location				0.363				0.553
Lower	222	121 (41.3)	101 (36.9)		109	62 (42.2)	47 (34.6)
Middle	112	50 (17.1)	62 (22.6)		50	26 (17.7)	24 (17.6)
Upper	156	80 (27.3)	76 (27.7)		74	36 (24.5)	38 (27.9)
Mixed	77	42 (14.3)	35 (12.8)		50	23 (15.6)	27 (19.9)
Tumor size (mm, mean ± SD)		45.9 (± 22.3)	56.7 (± 26.6)	< 0.001		47.2 (± 22.9)	54.2 (24.8)	0.014
Histologic type				0.902				0.613
Differentiated	92	47 (16.0)	45 (16.4)		52	25 (17.0)	27 (19.9)
Undifferentiated	475	246 (84.0)	229 (83.6)		231	122 (83.0)	109 (80.1)
Lymphovascular invasion				0.662				0.910
No	394	206 (70.3)	188 (68.6)		178	159 (65.4)	33 (53.2)
Yes	173	87 (29.7)	86 (31.4)		113	84 (34.6)	29 (46.8)
Adjuvant chemotherapy				0.346				0.355
No	137	66 (22.5)	71 (25.9)		68	32 (21.8)	36 (26.5)
Yes	430	227 (77.5)	203 (74.1)		215	115 (78.2)	100 (73.5)

SD: Standard deviation; BPM: Blood parameters.